glp-1 medication competitors pharmaceutical companies What to Make of the Coverage and Cost Landscape New policy on glp-1 medications

Clinical trials have demonstrated an average weight reduction of 15% over 68 weeks

Wegovy (semaglutide) and Zepbound (tirzepatide) are the two FDA-approved options for weight management

Cardiovascular outcomes trials in type 2 diabetes: where do we go from here

Its a chronic illness, just like high blood pressure, heart disease, diabetes, and it should be managed similar to these other chronic illnesses. The law speaks to the fact that obesity is no longer being treated like a character flaw or a lack of willpower, said Schauer, who is the director of the Metamor Metabolic Institute in Baton Rouge, a partnership between LSU's Pennington Biomedical Research Center and Our Lady of the Lake